{"id":"NCT03717506","sponsor":"Balmoral Medical company","briefTitle":"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-10","primaryCompletion":"2020-02-17","completion":"2020-04-16","firstPosted":"2018-10-24","resultsPosted":"2021-05-04","lastUpdate":"2021-05-04"},"enrollment":1236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"GDC 268 Lotion","otherNames":[]},{"type":"DRUG","name":"Clindamycin Phosphate Lotion 1%","otherNames":[]},{"type":"DRUG","name":"GDC Vehicle Lotion","otherNames":[]}],"arms":[{"label":"Test product","type":"EXPERIMENTAL"},{"label":"Reference Product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study is to evaluate the safety, tolerability, and therapeutic equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the efficacy of these two products to the GDC vehicle lotion (i.e., placebo) in the treatment of acne vulgaris.","primaryOutcome":{"measure":"Mean Percent Change in the Number of Inflamed Lesions","timeFrame":"12 weeks","effectByArm":[{"arm":"Test Product","deltaMin":-39.4,"sd":36.1},{"arm":"Reference Product","deltaMin":-40,"sd":36.83},{"arm":"Placebo","deltaMin":-35.1,"sd":35.54}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":496},"commonTop":[]}}